Brief: Acurx Receives Positive Regulatory Guidance From EMA For Ibezapolstat Phase 3 Program For CDI
06/01/2025 14:56
Jan 6 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O :
* ACURX RECEIVES POSITIVE REGULATORY GUIDANCE FROM EMA FOR
IBEZAPOLSTAT PHASE 3 PROGRAM FOR C. DIFFICILE INFECTION (CDI)
Source text: urn:newsml:reuters.com:*:nPn3jr0p8a
Further company coverage: ACXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acurx Pharmaceuticals
See all newsAcurx Pharmaceuticals Q1 net loss narrows as expenses fall
Brief: Acurx Pharmaceuticals To Discuss First Quarter 2026 Financial Results On May 12, 2026 Conference Call And Provide Business Update
Brief: Acurx Pharmaceuticals, Inc. Announces Closing Of Up To $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend
Acurx Pharma Q3 net loss narrows to $2 mln